Clinical Trials Logo

Biliary Tract Neoplasms clinical trials

View clinical trials related to Biliary Tract Neoplasms.

Filter by:

NCT ID: NCT02558959 Completed - Clinical trials for Biliary Tract Neoplasms

Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

Start date: September 1, 2015
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the effect of second-line irinotecan and capecitabine versus irinotecan alone for gemcitabine and cisplatin refractory advanced biliary tract cancer patients.

NCT ID: NCT02489422 Completed - Depression Clinical Trials

Programs To Support You During Chemotherapy

PRO-YOU
Start date: August 2016
Phase: N/A
Study type: Interventional

This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy. Possible mediators such as psychological stress, circadian disruption, and inflammation, will also be explored.

NCT ID: NCT02460432 Completed - Clinical trials for Pancreatic Neoplasms

Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)

Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effectiveness and safety of Niti-S Mira-Cover III Biliary Stent with Comvi Biliary Covered Stent for the treatment of malignant biliary obstruction.

NCT ID: NCT02443324 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Start date: July 29, 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

NCT ID: NCT02433639 Completed - Clinical trials for Biliary Tract Cancer

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Start date: April 2015
Phase: Phase 2
Study type: Interventional

Biliary tract cancer is relatively rare cancer, with generally poor prognosis. In metastatic/recurrent biliary tract cancer, the most commonly used 1st-line chemotherapy is gemcitabine+cisplatin combination. However, there is no standard 2nd-line chemotherapy and there is no validated targeted therapeutic agent, even though this tumor harbors diverse genetic characteristics. TH-302 (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophos-phate is a nitroimidazole-linked prodrug of a brominated version of isophosphoramide mustard (Br-IPM). When exposed to hypoxic conditions, TH-302 is reduced at the nitroimadazole site of the prodrug by intracellular reductases leading to the release of Br-IPM. Br-IPM can then act as a DNA crosslinking agent. In areas of normoxia, TH-302 remains intact as a prodrug and toxicity is minimized. In addition, preclinical data suggest that after activation, the active moiety may diffuse to areas outside the hypoxic region, demonstrating a "bystander" effect and possibly exhibiting additional anti-tumor activity. It is well known that biliary tract cancer is hypovascular tumor, so it contains large hypoxic area in the tumor. Therefore it would be worthy to test TH-302 in biliary tract cancer. This study is a phase II study of TH-302 monotherapy as second-line treatment in advanced biliary tract cancer, to investigate efficacy and safety of TH-302 monotherapy.

NCT ID: NCT02425137 Completed - Clinical trials for Advanced Biliary Tract Cancer(BTC)

A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Start date: April 2015
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients with advanced biliary tract cancer Secondary Objectives: - To evaluate overall response rate (ORR) - To evaluate progression-free survival (PFS) - To evaluate overall survival (OS) - To assess the safety profile

NCT ID: NCT02386397 Completed - Digestive Cancer Clinical Trials

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

BREGO
Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib administered in combination with mGEMOX in patients with advanced biliary tract cancer.

NCT ID: NCT02351765 Completed - Cholangiocarcinoma Clinical Trials

ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers

ABC-08
Start date: January 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended phase II dose, and to assess the safety of acelarin in combination with cisplatin in patients with locally advanced/ metastatic biliary tract cancers.

NCT ID: NCT02346032 Completed - Clinical trials for Biliary Tract Cancer

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

Start date: June 30, 2015
Phase: Phase 2
Study type: Interventional

Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma

NCT ID: NCT02182778 Completed - Clinical trials for Biliary Tract Cancer

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Start date: July 9, 2014
Phase: Phase 3
Study type: Interventional

To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for unresectable biliary tract cancer.